Press Release: BioXell To Regain Rights To TREM Platform Following StrategicDecision By Merck - FierceBiotech - Biotechnology Articles, Biotech Indust

Press Release: BioXell To Regain Rights To TREM Platform Following StrategicDecision By Merck - FierceBiotech - Biotechnology Articles, Biotech Industry News, FDA Approval News: "Milan, Switzerland, July 20, 2007 - Milan, Italy, July 20, 2007 - BioXell S.p.A. today announced that it will regain rights to its TREM platform from its collaboration partner, Merck & Co., Inc. This follows a strategic decision by Merck to streamline its focus in this area. In view of scientific progress of TREM-1 for sepsis, BioXell intends to seek another pharmaceutical partner to continue development of the platform."